Related Experiment Video
Updated: Aug 23, 2026
Murine Model of CD40-activation of B cells
Published on: March 5, 2010
The role of CD40 ligand in systemic lupus erythematosus
1Division of Rheumatology, University of California San Francisco, San Francisco, USA.
Insights
CD40 ligand (CD40L) is crucial for immune responses. Anti-CD40L antibodies show promise in models but face challenges in human trials for diseases like lupus.
Area of Science:
- Immunology
- Autoimmunity
- Protein interactions
Background:
- CD40 ligand (CD40L) is a transmembrane protein vital for immune function.
- Its interaction with CD40 on B cells regulates differentiation and antibody production.
- Abnormal CD40L expression is implicated in systemic lupus erythematosus (SLE) pathogenesis.
Purpose of the Study:
- To review in vitro and murine model data on anti-CD40L monoclonal antibodies.
- To summarize human clinical trial outcomes for anti-CD40L therapies.
- To assess the therapeutic potential and challenges of targeting CD40L in autoimmune diseases.
Main Methods:
- In vitro studies of CD40L-CD40 interactions.
- Murine models investigating anti-CD40L antibody efficacy.
- Analysis of human clinical trial data for anti-CD40L monoclonal antibodies.
Main Results:
- Murine models and in vitro data suggest therapeutic potential for anti-CD40L antibodies.
- Human clinical trials have shown limited efficacy.
- Adverse events have been reported in human trials involving anti-CD40L antibodies.
Conclusions:
- Targeting CD40L remains a complex therapeutic strategy.
- Further research is needed to overcome efficacy and safety challenges in human trials.
- Understanding CD40L's role in SLE and other autoimmune conditions is critical.
Abstract:
CD40 ligand (CD40L, also known as CD154 or gp39) is a member of the tumor necrosis superfamily of transmembrane proteins. The interaction of CD40L on activated T cells with its receptor, CD40 on B cells, is necessary for normal immune function, including B cell differentiation, germinal center formation, and antibody isotype switching. Abnormal expression of CD40L in patients with systemic lupus erythematosus (SLE) may contribute to autoantibody production and disease pathogenesis. Although murine models of monoclonal antibodies directed against CD40L initially showed promise, human trials either have failed to demonstrate efficacy or have been associated with adverse events. This review will summarize in vitro and murine model data and human clinical trials involving anti-CD40L monoclonal antibody.
